Accéder au contenu
Merck

Cloricromene reduces myocardial infarct size in rabbits when administered during the early reperfusion period.

Anesthesia and analgesia (1997-02-01)
D A Zvara, H J Galaska, V P Castellano, J Vinten-Johansen, R L Royster, M W Williams, B A Murphy, E J Kim
RÉSUMÉ

Cloricromene is a coumarin derivative without anticoagulant activities that has recently been found to decrease myocardial infarct size after an ischemic-reperfusion injury. This study seeks to determine when the cardioprotective action of cloricromene is exerted in an in vivo rabbit model of ischemic-reperfusion injury. Forty-nine rabbits subjected to 30 min of coronary occlusion and 120 min of reperfusion were randomized into five groups: VEH (n = 11) received saline vehicle; IR (n = 9) received an infusion of cloricromene starting at the onset of ischemia at 8 micrograms.kg-1.min-1; R(-5)(n = 9) and R(+30)(n = 9) received an infusion of cloricromene at 8 micrograms.kg-1.min-1 starting 5 min before reperfusion and 30 min after reperfusion, respectively; and RB(-5)(n = 11) received 300 micrograms/kg bolus of cloricromene 5 min before reperfusion followed by an infusion of 8 micrograms.kg-1.min-1. All infusions were continued until the end of the reperfusion period. Myocardial infarct size was significantly reduced in groups IR, R(-5), and RB(-5). We conclude that cloricromene's effective time of action occurs prior to the first 30 min of the reperfusion period.